OLAPLEX Reports First Quarter 2024 Results

Reiterates Fiscal Year 2024 Guidance

NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) — Olaplex Holdings, Inc. NASDAQ: OLPX (“OLAPLEX” or the “Company”) today announced financial results for the first quarter ended March 31, 2024.

Amanda Baldwin, OLAPLEX’s Chief Executive Officer, commented: “Our first quarter results represent progress on the business transformation plan that we outlined earlier this year. I am encouraged with our performance to date and believe we are well-positioned to achieve our goals for 2024.”

For the first quarter 2024 compared to the first quarter 2023:

  • Net sales decreased 13.1% to $98.9 million;
    • By channel:
      • Professional decreased 19.9% to $38.7 million;
      • Specialty Retail decreased 1.2% to $34.4 million;
      • Direct-To-Consumer decreased 15.7% to $25.7 million;
    • Net sales increased 2.5% in the United States and decreased 24.3% internationally
  • Net income decreased 63.1% and adjusted net income decreased 34.4%;
  • Diluted EPS was $0.01 for the first quarter 2024, as compared to $0.03 for the first quarter 2023;
  • Adjusted Diluted EPS was $0.03 for the first quarter 2024, as compared to $0.05 for the first quarter 2023

First Quarter 2024 Results

(Dollars in $000’s, except per share data)          
  Q1 2024   Q1 2023   % Change
Net Sales $ 98,906     $ 113,787       (13.1 )%
Gross Profit $ 71,343     $ 80,810       (11.7 )%
Gross Profit Margin   72.1 %     71.0 %    
Adjusted Gross Profit $ 73,530     $ 82,576       (11.0 )%
Adjusted Gross Profit Margin   74.3 %     72.6 %    
SG&A $ 40,437     $ 34,924       15.8 %
Adjusted SG&A $ 37,249     $ 32,904       13.2 %
Net Income $ 7,746     $ 20,964       (63.1 )%
Adjusted Net Income $ 20,584     $ 31,399       (34.4 )%
Adjusted EBITDA $ 35,484     $ 50,029       (29.1 )%
Adjusted EBITDA Margin   35.9 %     44.0 %    
Diluted EPS $ 0.01     $ 0.03       (66.7 )%
Adjusted Diluted EPS $ 0.03     $ 0.05       (40.0 )%
Weighted Average Diluted Shares Outstanding   663,565,291       683,485,182      

Adjusted gross profit, adjusted gross profit margin, adjusted SG&A, adjusted net income, adjusted EBITDA, adjusted EBITDA margin, and adjusted diluted EPS are measures that are not calculated or presented in accordance with generally accepted accounting principles in the United States (“GAAP”). For more information about how we use these non-GAAP financial measures in our business, the limitations of these measures, and a reconciliation of these measures to the most directly comparable GAAP measures, please see “Disclosure Regarding Non-GAAP Financial Measures” and the reconciliation tables that accompany this release.

Balance Sheet
As of March 31, 2024, the Company had $507.5 million of cash and cash equivalents, compared to $466.4 million as of December 31, 2023. Inventory at the end of the first quarter 2024 was $94.6 million, compared to $95.9 million at December 31, 2023. Long-term debt, net of current portion and deferred debt issuance costs was $647.7 million as of March 31, 2024, compared to $649.0 million as of December 31, 2023.

Fiscal Year 2024 Guidance

The Company is reiterating guidance for net sales, adjusted net income and adjusted EBITDA for fiscal year 2024, as initially disclosed by the Company on February 29, 2024. The Company’s fiscal year 2024 guidance outlined below incorporates management’s expectations regarding consumer demand, and investments and actions aimed at driving sell-through, improving upon foundational capabilities, and building a healthier brand.

For Fiscal 2024:      
(Dollars in millions) Fiscal Year 2024 Fiscal Year 2023 Actual % change
Net Sales $435-$463 $458 (5)% to 1%
Adjusted Net Income* $87-$100 $108 (20)% to (8)%
Adjusted EBITDA* $143-$159 $174 (18)% to (9)%

The fiscal year 2024 net sales, adjusted net income and adjusted EBITDA guidance are approximations and are based on the Company’s plans and assumptions for the relevant period, including, but not limited to, the following:

  • Adjusted Gross Profit Margin:
    • The Company anticipates adjusted gross profit margin* in the range of 72.5% to 73.1% in fiscal year 2024, compared to 71.4% in fiscal year 2023, due primarily to the lapping of actions taken by the Company to address excess inventory in fiscal year 2023, as well as anticipated efficiencies derived from an internal cost savings program in fiscal year 2024, which is expected to more than offset modestly higher product costs.
  • Adjusted SG&A:
    • The Company expects adjusted SG&A* in the range of $172 million to $179 million in fiscal year 2024, an increase of $19 million to $26 million as compared to fiscal year 2023. The increase is expected to be primarily attributable to higher sales and marketing expenses and higher organizational costs due to annualizing the expense of headcount additions made during fiscal 2023.
  • Adjusted EBITDA Margin:
    • The Company expects adjusted EBITDA margin* in the range of 32.8% to 34.3% for fiscal year 2024.
  • Net Interest Expense:
    • The Company expects net interest expense to be approximately $32 million to $34 million during fiscal year 2024.
  • Adjusted Effective Tax Rate:
    • The Company expects an adjusted effective tax rate* of approximately 19.5% to 20.5% for fiscal year 2024.

*Adjusted net income, adjusted EBITDA, adjusted gross profit margin, adjusted SG&A, adjusted EBITDA margin and adjusted effective tax rate are non-GAAP measures. See “Disclosure Regarding Non-GAAP Financial Measures” for additional information.

Webcast and Conference Call Information

The Company plans to host an investor conference call and webcast to review first quarter 2024 financial results at 9:00am ET/6:00am PT on May 2, 2024. The webcast can be accessed at https://ir.olaplex.com. The conference call can be accessed by calling (201) 689-8521 or (877) 407-8813 for a toll-free number. A replay of the webcast will remain available on the website for 90 days.

About OLAPLEX

OLAPLEX is an innovative, science-enabled, technology-driven beauty company with a mission to improve the hair health of its consumers. In 2014, OLAPLEX disrupted and revolutionized the prestige hair care category by creating innovative bond-building technology, which works by protecting, strengthening and relinking broken bonds in the hair during and after hair services. The brand’s proprietary, patent-protected ingredient works on a molecular level to protect and repair damaged hair. OLAPLEX’s award-winning products are sold through an expanding omnichannel model serving the professional, specialty retail, and direct-to-consumer channels.

Cautionary Note Regarding Forward-Looking Statements

This press release includes certain forward-looking statements and information relating to the Company that are based on the beliefs of management as well as assumptions made by, and information currently available to, the Company. These forward-looking statements include, but are not limited to, statements about: the Company’s financial position, operating results, growth, sales and profitability; the Company’s financial guidance for fiscal year 2024, including net sales, adjusted net income, adjusted EBITDA, adjusted gross profit margin, adjusted SG&A, adjusted EBITDA margin, net interest expense, adjusted effective tax rate and non-employee marketing and advertising expenses; demand for the Company’s products; the Company’s product development pipeline and the impact of new product introductions, including the timing thereof; changes in the Company’s distribution; the Company’s business plans, strategies, investments, priorities and objectives, including the impact and timing thereof; the impact of the Company’s internal cost savings program; anticipated product costs and organizational costs; the Company’s sales, marketing and education initiatives and related investments, and the impact, focus and timing thereof; general economic trends; the Company’s employees and corporate culture; growth and expansion opportunities, including expansion in existing markets and into new markets; the Company’s executive leadership changes; inventory levels; seasonality; and other statements contained in this press release that are not historical or current facts. When used in this press release, words such as “may,” “will,” “could,” “should,” “intend,” “potential,” “continue,” “anticipate,” “believe,” “estimate,” “expect,” “plan,” “target,” “predict,” “project,” “forecast,” “seek” and similar expressions as they relate to the Company are intended to identify forward-looking statements.

The forward-looking statements in this press release reflect the Company’s current expectations and projections about future events and financial trends that management believes may affect the Company’s business, financial condition and results of operations. These statements are predictions based upon assumptions that may not prove to be accurate, and they are not guarantees of future performance. As such, you should not place significant reliance on the Company’s forward-looking statements. Neither the Company nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements, including any such statements taken from third party industry and market reports.

Forward-looking statements involve known and unknown risks, inherent uncertainties and other factors that are difficult to predict which may cause the Company’s actual results, performance, time frames or achievements to be materially different from any future results, performance, time frames or achievements expressed or implied by the forward-looking statements, including, without limitation: competition in the beauty industry; the Company’s ability to effectively maintain and promote a positive brand image, expand its brand awareness and maintain consumer confidence in the quality, safety and efficacy of its products; the Company’s ability to anticipate and respond to market trends and changes in consumer preferences and execute on its growth strategies and expansion opportunities, including with respect to new product introductions; the Company’s ability to accurately forecast customer and consumer demand for its products; the Company’s dependence on the success of its long-term strategic plan; the Company’s ability to limit the illegal distribution and sale by third parties of counterfeit versions of its products or the unauthorized diversion by third parties of its products; the Company’s dependence on a limited number of customers for a large portion of its net sales; the Company’s ability to develop, manufacture and effectively and profitably market and sell future products; the Company’s ability to attract new customers and consumers and encourage consumer spending across its product portfolio; the Company’s ability to successfully implement new or additional marketing efforts; the Company’s relationships with and the performance of its suppliers, manufacturers, distributors and retailers and the Company’s ability to manage its supply chain; impacts on the Company’s business from political, regulatory, economic, trade and other risks associated with operating internationally; the Company’s ability to manage its executive leadership changes and to attract and retain senior management and other qualified personnel; the Company’s reliance on its and its third-party service providers’ information technology; the Company’s ability to maintain the security of confidential information; the Company’s ability to establish and maintain intellectual property protection for its products, as well as the Company’s ability to operate its business without infringing, misappropriating or otherwise violating the intellectual property rights of others; the outcome of litigation and regulatory proceedings; the impact of changes in federal, state and international laws, regulations and administrative policy; the Company’s existing and any future indebtedness, including the Company’s ability to comply with affirmative and negative covenants under its credit agreement; the Company’s ability to service its existing indebtedness and obtain additional capital to finance operations and its growth opportunities; volatility of the Company’s stock price; the Company’s “controlled company” status and the influence of investment funds affiliated with Advent International, L.P. over the Company; the impact of an economic downturn and inflationary pressures on the Company’s business; fluctuations in the Company’s quarterly results of operations; changes in the Company’s tax rates and the Company’s exposure to tax liability; and the other factors identified under the heading “Risk Factors” in Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) and in the other documents that the Company files with the SEC from time to time.

Many of these factors are macroeconomic in nature and are, therefore, beyond the Company’s control. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company’s actual results, performance or achievements may vary materially from those described in this press release as anticipated, believed, estimated, expected, intended, planned or projected. The forward-looking statements in this press release represent management’s views as of the date hereof. Unless required by law, the Company neither intends nor assumes any obligation to update these forward-looking statements for any reason after the date hereof to conform these statements to actual results or to changes in the Company’s expectations or otherwise.

Disclosure Regarding Non-GAAP Financial Measures

In addition to the financial measures presented in this release in accordance with GAAP, the Company has included certain non-GAAP financial measures, including adjusted EBITDA, adjusted EBITDA margin, adjusted net income, adjusted effective tax rate, adjusted gross profit, adjusted gross profit margin, adjusted SG&A and adjusted diluted EPS. Management believes these non-GAAP financial measures, when taken together with the Company’s financial results presented in accordance with GAAP, provide meaningful supplemental information regarding the Company’s operating performance and facilitate internal comparisons of its historical operating performance on a more consistent basis by excluding certain items that may not be indicative of its business, results of operations or outlook. In particular, management believes that the use of these non-GAAP measures may be helpful to investors as they are measures used by management in assessing the health of the Company’s business, determining incentive compensation and evaluating its operating performance, as well as for internal planning and forecasting purposes.

The Company calculates adjusted EBITDA as net income, adjusted to exclude: (1) interest expense, net; (2) income tax provision; (3) depreciation and amortization; (4) share-based compensation expense; (5) non-ordinary inventory adjustments; (6) non-ordinary costs and fees; (7) non-ordinary legal costs; and (8) Tax Receivable Agreement liability adjustments. The Company calculates adjusted EBITDA margin by dividing adjusted EBITDA by net sales. The Company calculates adjusted net income as net income, adjusted to exclude: (1) amortization of intangible assets (excluding software); (2) non-ordinary costs and fees; (3) non-ordinary legal costs; (4) non-ordinary inventory adjustments; (5) share-based compensation expense; (6) Tax Receivable Agreement liability adjustment; and (7) tax effect of non-GAAP adjustments. The Company calculates adjusted effective tax rate as effective income tax rate, adjusted to exclude the tax effect of non-GAAP adjustments referenced in item (7) of the immediately preceding sentence. The Company calculates adjusted gross profit as gross profit, adjusted to exclude: (1) non-ordinary inventory adjustments and (2) amortization of patented formulations pertaining to the acquisition of the Olaplex, LLC business in 2020 by certain investment funds affiliated with Advent International, L.P. and other investors (the “Acquisition”). The Company calculates adjusted gross profit margin by dividing adjusted gross profit by net sales. The Company calculates adjusted SG&A as SG&A, adjusted to exclude: (1) share-based compensation expense; (2) non-ordinary legal costs; and (3) non-ordinary costs and fees. The Company calculates adjusted basic and diluted EPS as adjusted net income divided by weighted average basic and diluted shares outstanding, respectively. Please refer to “Reconciliation of Non-GAAP Financial Measures to GAAP Equivalents” located in the financial supplement in this release for further information regarding these adjustments for the periods presented.

Please refer to “Reconciliation of Non-GAAP Financial Measures to GAAP Equivalents” located in the financial supplement in this release for a reconciliation of these non-GAAP metrics to their most directly comparable financial measure stated in accordance with GAAP.

This release includes forward-looking guidance for adjusted EBITDA, adjusted EBITDA margin, adjusted net income, adjusted gross profit margin, adjusted effective tax rate and adjusted SG&A. The Company is not able to provide, without unreasonable effort, a reconciliation of the guidance for adjusted EBITDA, adjusted EBITDA margin, adjusted net income, adjusted gross profit margin, adjusted effective tax rate and adjusted SG&A to the most directly comparable GAAP measure because the Company does not currently have sufficient data to accurately estimate the variables and individual adjustments included in the most directly comparable GAAP measure that would be necessary for such reconciliations, including (a) income tax related accruals in respect of certain one-time items, (b) costs related to potential debt or equity transactions, and (c) other non-recurring expenses that cannot reasonably be estimated in advance. These adjustments are inherently variable and uncertain and depend on various factors that are beyond the Company’s control and as a result it is also unable to predict their probable significance. Therefore, because management cannot estimate on a forward-looking basis without unreasonable effort the impact these variables and individual adjustments will have on its reported results in accordance with GAAP, it is unable to provide a reconciliation of the non-GAAP measures included in its fiscal 2024 guidance.

CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except shares)
(Unaudited)
 
  March 31,
2024
  December 31,
2023
Assets      
Current Assets:      
Cash and cash equivalents $ 507,506     $ 466,400  
Accounts receivable, net of allowances of $19,079 and $21,465   25,807       40,921  
Inventory   94,643       95,922  
Other current assets   11,541       9,953  
Total current assets   639,497       613,196  
Property and equipment, net   1,241       930  
Intangible assets, net   935,917       947,714  
Goodwill   168,300       168,300  
Other assets   8,416       10,198  
Total assets $ 1,753,371     $ 1,740,338  
       
Liabilities and stockholders’ equity      
Current Liabilities:      
Accounts payable $ 17,222     $ 7,073  
Sales and income taxes payable   4,923       9,067  
Accrued expenses and other current liabilities   18,156       20,576  
Current portion of long-term debt   6,750       6,750  
Current portion of Related Party payable pursuant to Tax Receivable Agreement   12,675       12,675  
Total current liabilities   59,726       56,141  
Long-term debt   647,695       649,023  
Deferred tax liabilities   2,678       3,016  
Related Party payable pursuant to Tax Receivable Agreement   185,496       185,496  
Other liabilities   2,065       1,694  
Total liabilities   897,660       895,370  
       
Contingencies      
       
Stockholders’ equity (Notes 1 and 9):      
Common stock, $0.001 par value per share; 2,000,000,000 shares authorized, 661,283,677 and 660,731,935 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively   675       671  
Preferred stock, $0.001 par value per share; 25,000,000 shares authorized and no shares issued and outstanding          
Additional paid-in capital   319,843       316,489  
Accumulated other comprehensive income   1,004       1,365  
Retained earnings   534,189       526,443  
Total stockholders’ equity   855,711       844,968  
Total liabilities and stockholders’ equity $ 1,753,371     $ 1,740,338  

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(amounts in thousands, except per share and share data)
(Unaudited)
   
  Three Months Ended
March 31,
    2024       2023  
Net sales $ 98,906     $ 113,787  
Cost of sales:      
Cost of product (excluding amortization)   25,376       31,235  
Amortization of patented formulations   2,187       1,742  
Total cost of sales   27,563       32,977  
Gross profit   71,343       80,810  
Operating expenses:      
Selling, general, and administrative   40,437       34,924  
Amortization of other intangible assets   11,289       10,323  
Total operating expenses   51,726       45,247  
Operating income   19,617       35,563  
Interest expense   (14,504 )     (13,918 )
Interest income   6,203       3,375  
Other (expense) income, net   (947 )     242  
Income before provision for income taxes   10,369       25,262  
Income tax provision   2,623       4,298  
Net income $ 7,746     $ 20,964  
Net income per share:      
Basic $ 0.01     $ 0.03  
Diluted $ 0.01     $ 0.03  
Weighted average common shares outstanding:      
Basic   660,821,930       651,730,993  
Diluted   663,565,291       683,485,182  
       
Other comprehensive loss:      
Unrealized loss on derivatives, net of income tax effect $ (361 )   $ (557 )
Total other comprehensive loss   (361 )     (557 )
Comprehensive income $ 7,385     $ 20,407  

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(amounts in thousands)
(Unaudited)
 
  Three Months Ended
March 31,
    2024       2023  
Cash flows from operating activities      
Net income $ 7,746     $ 20,964  
Adjustments to reconcile net income to net cash provided by operating activities:   35,961       27,125  
Net cash provided by operating activities   43,707       48,089  
Net cash used in investing activities   (1,084 )     (631 )
Net cash used in financing activities   (1,517 )     (926 )
Net increase in cash and cash equivalents   41,106       46,532  
Cash and cash equivalents – beginning of period   466,400       322,808  
Cash and cash equivalents – end of period $ 507,506     $ 369,340  


Reconciliation of Non-GAAP Financial Measures to GAAP Equivalents

The following tables present a reconciliation of net income, gross profit and SG&A, as the most directly comparable financial measure stated in accordance with U.S. GAAP, to adjusted EBITDA, adjusted EBITDA margin, adjusted gross profit, adjusted gross profit margin, adjusted SG&A, adjusted net income and adjusted net income per share for each of the periods presented.

  Three Months Ended
March 31,
(in thousands)   2024       2023  
Reconciliation of Net Income to Adjusted EBITDA      
Net income $ 7,746     $ 20,964  
Depreciation and amortization of intangible assets   13,626       12,180  
Interest expense, net   8,301       10,543  
Income tax provision   2,623       4,298  
Share-based compensation   3,183       2,018  
Inventory write off and disposal(1)         24  
Executive reorganization cost(2)   5       2  
Adjusted EBITDA $ 35,484     $ 50,029  
Adjusted EBITDA margin   35.9 %     44.0 %

  Three Months Ended
March 31,
(in thousands)   2024       2023  
Reconciliation of Gross Profit to Adjusted Gross Profit      
Gross profit $ 71,343     $ 80,810  
Amortization of patented formulations   2,187       1,742  
Inventory write off and disposal(1)         24  
Adjusted gross profit $ 73,530     $ 82,576  
Adjusted gross profit margin   74.3 %     72.6 %

  Three Months Ended
March 31,
(in thousands)   2024       2023  
Reconciliation of SG&A to Adjusted SG&A      
SG&A $ 40,437     $ 34,924  
Share-based compensation   (3,183 )     (2,018 )
Executive reorganization cost(2)   (5 )     (2 )
Adjusted SG&A $ 37,249     $ 32,904  

  Three Months Ended
March 31,
(in thousands, except per share data)   2024       2023  
Reconciliation of Net Income to Adjusted Net Income      
Net income $ 7,746     $ 20,964  
Amortization of intangible assets (excluding software)   12,369       11,923  
Share-based compensation   3,183       2,018  
Inventory write off and disposal(1)         24  
Executive reorganization cost(2)   5       2  
Tax effect of adjustments   (2,719 )     (3,532 )
Adjusted net income $ 20,584     $ 31,399  
Adjusted net income per share:      
Basic $ 0.03     $ 0.05  
Diluted $ 0.03     $ 0.05  
               
(1) The inventory write-off and disposal costs relate to unused stock of a product that the Company reformulated in June 2021 as a result of regulation changes in the E.U. In the interest of having a single formulation for sale worldwide, the Company reformulated on a global basis and is disposing of unused stock.       
(2) Represents ongoing benefit payments associated with the departure of the Company’s Chief Operating Officer that occurred in fiscal year 2022.       
               

Contacts:
Investors:

Patrick Flaherty
Vice President, Investor Relations
patrick.flaherty@olaplex.com

Financial Media:

Lisa Bobroff
Vice President, Global Communications & Consumer Engagement
lisa.bobroff@olaplex.com

OLAPLEX Reports First Quarter 2024 Results
Olaplex Holdings Inc OLAPLEX Reports First Quarter 2024 Results